Boehringer Ingelheim recently announced that the Phase 3 clinical trial studying empagliflozin in adults with chronic kidney disease (CKD) will stop early based on a recommendation from the trial's...
Moderna recently dosed the first participant in an HIV trimer mRNA vaccine (mRNA-1574) clinical trial.
The open-label Phase 1 trial will evaluate the safety and immunogenicity of...
Pfizer recently announced that a Clostridioides difficile (C. difficile) vaccine candidate did not meet its primary endpoint of C. difficile infection (CDI) prevention, but was 100- percent effective...
Novo Nordisk recently expanded its research collaboration in oral drug delivery technologies with the Massachusetts Institutes of Technology (MIT) and Brigham and Women’s Hospital...
Gilead recently announced that the Phase 3 clinical trial of Trodelvy in patients with HR/HER2-metastatic breast cancer met its primary endpoint.
The Phase 3 TROPiCS-02 study evaluated Trodelvy versus...
Boehringer Ingelheim and precision medicine software company Lifebit Biotech recently partnered to build a scalable data, analytics, and infrastructure platform to unlock the transformation value of...
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recently adopted a positive opinion for Pfizer and Biohaven’s generic drug to treat migraine...
Gilead recently announced one-year results from an ongoing Phase 2/3 CAPELLA trial evaluating its HIV-1 capsid inhibitor, lenacapavir, in individuals with multi-drug resistant HIV.
The trial...
Merck recently announced that Keytruda, combined with chemotherapy and followed by Keytruda as monotherapy, prolonged event-free survival compared to chemotherapy followed by placebo in patients with...
Abbott recently announced the world's first implant of a dual-chamber leadless pacemaker system as part of its Aveir DR i2i pivotal clinical trial.
The prospective investigational study will...
Biogen recently exercised its option to participate in the development and commercialization of Genentech’s bispecific antibody, mosunetuzumab.
Mosunetuzumab is a CD20xCD3 T-cell engaging...
Pfizer and Valneva recently announced further positive results from the Phase 2 clinical trial evaluating their Lyme disease vaccine candidate, VLA15.
The trial, VLA15-221, enrolled 294 healthy adult...
AstraZeneca recently announced that Imfinzi combined with standard-of-care chemotherapy significantly improved overall survival and progression-free survival in patients with advanced biliary tract...
The National Institutes of Health (NIH) recently launched the first phase of Neuromod Prize, a $9.8 million competition to accelerate the development of neuromodulation therapies.
Neuromodulation...
Moderna and Carisma Therapeutics recently entered into an agreement to discover, develop, and commercialize in vivo engineered chimeric antigen receptor monocyte (CAR-M) cancer...
Pfizer and Beam Therapeutics recently entered into a four-year collaboration focused on in vivo base editing programs to generate precision medicine for rare diseases of the liver, muscle, and central...
GSK recently appointed Tony Wood as chief executive officer (CSO), replacing current CSO Hal Barron.
Wood, a highly respected scientist and one of the world’s pre-eminent chemists, has over 30...
Pfizer and Biohaven recently completed a collaboration transaction to commercialize small molecule migraine drugs, rimegepant and zavegepant, outside the US.
Rimegepant, commercialized as Nurtex ODT...
Pfizer and Acuitas Therapeutics recently entered into a development and option agreement under which Pfizer will license Acuitas’ lipid nanoparticle (LNP) technology for up to 10 mRNA vaccine or...
Convalescent plasma from patients who have recovered from COVID-19 reduced hospitalizations by nearly 50% for outpatients infected with the virus in a nationwide, multicenter clinical trial.
Johns...
